-- Advanced next-generation gamma delta (<GAMMA> ) T cell engager (TCE)
platform demonstrating a novel mechanism for <GAMMA> T cell expansion,
deep target cell depletion, and favorable cytokine profile; Initial in
vivo data expected in the second half of 2026
-- Presented updated data at ASCO 2026 demonstrating median overall survival
(mOS) exceeding 19.5 months and still climbing, across all patients with
newly diagnosed glioblastoma (GBM) treated with repeat-dosing of
DeltEx$(TM)$ Drug Resistant Immunotherapy $(DRI)$
-- Published peer-reviewed clinical data from Phase 1 INB-200 trial in The
Journal of Clinical Oncology (JCO) demonstrating DeltEx(TM) DRI more than
doubled expected median progression-free survival (mPFS) in newly
diagnosed GBM
-- Reported new translational AI proteomic and immunogenomic analyses
demonstrating DeltEx DRI preserves immune function and positively
remodels the GBM tumor microenvironment, providing additional evidence
supporting its therapeutic efficacy potential
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (<GAMMA> ) T cell therapies and <GAMMA> T cell engagers (TCEs) for cancer and autoimmune diseases, today reported financial results and business highlights for the second quarter ended June 30, 2026.
"The second quarter marked an important period of scientific and clinical validation for <GAMMA> T cell therapeutics and IN8bio. Our <GAMMA> TCE platform is progressing, with INB-619 advancing into initial animal models. We are pleased to remain on track for reporting initial in vivo data this year," said William Ho, Chief Executive Officer and co-founder of IN8bio. "In addition, peer-reviewed and updated clinical data from our glioblastoma program continue to demonstrate a favorable safety profile and provide strong evidence that <GAMMA> T cells are clinically active and can be delivered safely to potentially improve patient outcomes. We remain focused on disciplined execution, as we continue to seek a regulatory pathway for our glioblastoma program, with the ultimate goal of bringing much needed treatment to patients."
Advancing Next-Generation <GAMMA> TCE Platform (INB-619)
-- Continued advancement of proprietary INB-600 platform of novel <GAMMA> T
cell engagers, designed to selectively eliminate targets such as CD19,
potentially reducing toxicities including cytokine release syndrome $(CRS)$
and infections, while expanding the therapeutic window compared with
conventional CD3-targeting T cell engagers.
-- Advancing INB-619, a CD19-targeting <GAMMA> T cell engager for oncology
and autoimmune diseases, into IND-enabling studies following encouraging
early preclinical data demonstrating complete B cell depletion, robust
<GAMMA> T cell expansion, and minimal CRS-associated cytokine release,
including IL-6 and TNF-<ALPHA>.
-- Remain on track to report initial in vivo preclinical data in the second
half of 2026.
Reported Clinical and Translational Advances for DeltEx(TM) DRI in Newly Diagnosed Glioblastoma
During the second quarter, IN8bio reported multiple clinical and scientific milestones supporting the clinical activity of <GAMMA> T cells and IN8bio's DeltEx(TM) DRI platform:
-- Published the first peer-reviewed clinical results of DeltEx DRI in newly
diagnosed GBM in The Journal of Clinical Oncology. Among all patients
treated, no dose-limiting toxicities (DLTs), CRS or immune effector
cell-associated neurotoxicity syndrome (ICANS) were observed.
-- Presented updated clinical data at the 2026 American Society of Clinical
Oncology (ASCO) Annual Meeting demonstrating encouraging survival benefit
in repeat-dose treated patients, with mPFS of 13.0 months versus 6.6
months for contemporaneously enrolled patients receiving only
standard-of-care $(SOC)$ and mOS exceeding 19.5+ months versus 13.2 months
for SOC.
-- Approximately 43% of repeat-dose patients remained alive at 24
months compared with 20% of SOC patients.
-- Presented new translational data at the International Society for Cell &
Gene Therapy (ISCT) and International Society for Cell & Gene Therapy
(ISCT) and American Society of Gene & Cell Therapy (ASGCT) Annual
Meetings integrating artificial intelligence (AI), immunogenomics,
histopathology, transcriptomics and spatial proteomics. Repeated
DeltEx(TM) DRI dosing demonstrated preserved immune function during
chemotherapy and positively remodeled the glioblastoma tumor
microenvironment.
-- Spatial proteomics analyses demonstrated an 18-fold increase in
intratumoral CD8+ T cell density and a 90% reduction in
immunosuppressive granulocytes, providing mechanistic support for
the clinical activity observed with DeltEx(TM) DRI.
-- IN8bio Chief Scientific Officer Lawrence Lamb co-authored a review in
Nature Communications highlighting advances in <GAMMA> T cell engineering,
<GAMMA> T cell engagers, CAR <GAMMA> T cells and combination
immunotherapy strategies, reinforcing IN8bio's scientific leadership in
the rapidly expanding <GAMMA> T cell field.
-- The publication highlights the potential of "off-the-shelf"
<GAMMA> T cell therapies, driven by the cells' lack of
graft-versus-host disease (GvHD), and the growing clinical
evidence supporting their application across hematologic
malignancies and solid tumors, including GBM.
Upcoming Anticipated Milestones
-- Report initial preclinical animal data for INB-619 in the second half of
2026.
-- Report on FDA discussions regarding the potential regulatory pathways for
the DeltEx(TM) DRI GBM program.
-- INB-100 program clinical update at a scientific meeting in late 2026.
-- Provide additional clinical and translational updates from the DeltEx(TM)
DRI GBM program.
Second Quarter 2026 Financial Highlights
-- Cash position: As of June 30, 2026, the Company had cash of $18.0 million,
compared with $13.2 million, for the comparable prior year period.
-- Research and Development (R&D) expenses: R&D expenses were $2.5 million
for the three months ended June 30, 2026, compared with $2.5 million for
the comparable prior year period. These amounts include non-cash items
such as stock-based compensation $(SBC)$ and depreciation.
-- General and administrative (G&A) expenses: G&A expenses were $2.4 million
for the three months ended June 30, 2026, compared with $2.7 million for
the comparable prior year period. These amounts include non-cash items
such as SBC and depreciation.
-- Net loss: The Company reported a net loss of $4.8 million, or $0.25 per
basic and diluted common share, for the three months ended June 30, 2026,
compared with a net loss of $5.1 million, or $1.24 per basic and diluted
common share, for the comparable prior year period.
About IN8bio
IN8bio is a clinical-stage biopharmaceutical company developing <GAMMA> T cell and <GAMMA> T cell engager (TCE) product candidates to address unmet medical needs. <GAMMA> T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company's pipeline is anchored by INB-600, a novel <GAMMA> T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic <GAMMA> T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified <GAMMA> T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.IN8bio.com.
Forward Looking Statements
This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "aims," "anticipates," "believes," "could," "estimates," "expects," "forecasts," "goal," "intends," "may," "plans," "possible," "potential," "seeks," "will" and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the therapeutic potential of IN8bio's product candidates; the potential of IN8bio's INB-600 platform to improve durability and safety compared with traditional CD3-targeting engagers; IN8bio's ability to achieve anticipated milestones, including receipt of guidance from the FDA on regulatory pathways for the DeltEx(TM) DRI GBM program, expected presentations and data readouts from its preclinical studies and clinical trials including preclinical in vivo data for INB-619, patient dosing timelines and advancement of clinical development plans; and other statements that are not historical fact. IN8bio may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including: risks to site initiation, clinical trial commencement, patient enrollment and follow-up, as well as IN8bio's ability to meet anticipated deadlines and milestones; uncertainties inherent in the initiation and completion of preclinical studies and clinical trials and clinical development of
IN8bio's product candidates; the risk that IN8bio may be unable to raise additional capital and could be forced to delay, further reduce or to explore other strategic options for certain of its development programs, or even terminate its operations; IN8bio's ability to continue to operate as a going concern; the risk that IN8bio may not realize the intended benefits of its DeltEx platform and TCE program; availability and timing of results from preclinical studies and clinical trials; whether the outcomes of preclinical studies will be predictive of clinical trial results; whether initial or interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; the risk that trials and studies may be delayed and may not have satisfactory outcomes; potential adverse effects arising from the testing or use of IN8bio's product candidates; the uncertainty of regulatory approvals to conduct trials or to market products; IN8bio's reliance on third parties, including licensors and clinical research organizations; and other important factors, any of which could cause IN8bio's actual results to differ from those contained in the forward-looking statements, which are described in greater detail in the section entitled "Risk Factors" in IN8bio's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 7, 2026, as well as in other filings IN8bio may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and IN8bio expressly disclaims any obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Investors and Corporate Contact:
IN8bio, Inc.
Patrick McCall
646.933.5603
pfmccall@IN8bio.com
Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com
IN8BIO, INC.
BALANCE SHEETS
(In thousands, except share and per share data)
June 30,
2026 December 31,
(unaudited) 2025
------------- --------------
Assets (Note 2)
Current assets
Cash $ 17,956 $ 27,092
Prepaid expenses and other current
assets 540 788
--------- ----------
Total Current Assets 18,496 27,880
--------- ----------
Non-current assets
Property and equipment, net 1,600 1,858
Restricted cash 176 220
Right-of-use assets - finance leases 125 296
Right-of-use assets - operating
leases 1,246 1,882
Other non-current assets 102 146
--------- ----------
Total Non-Current Assets 3,249 4,402
--------- ----------
Total Assets $ 21,745 $ 32,282
========= ==========
Liabilities and Stockholders' Equity
Liabilities
Current liabilities
Accounts payable $ 444 $ 309
Accrued expenses and other current
liabilities 761 1,633
Short-term finance lease liability 126 295
Short-term operating lease liability 923 924
--------- ----------
Total Current Liabilities 2,254 3,161
--------- ----------
Long-term operating lease liability 1,128 1,563
--------- ----------
Total Non-Current Liabilities 1,128 1,563
--------- ----------
Total Liabilities 3,382 4,724
--------- ----------
Stockholders' Equity
Preferred stock, par value $0.0001
per share; 10,000,000 shares
authorized at June 30, 2026 and
December 31, 2025, respectively; no
shares issued and outstanding -- --
Common stock, par value $0.0001 per
share; 490,000,000 shares
authorized at June 30, 2026 and
December 31, 2025; 9,853,121 and
9,766,132 shares issued and
outstanding at June 30, 2026 and
December 31, 2025, respectively 10 10
Additional paid-in capital 169,320 168,644
Accumulated deficit (150,967) (141,096)
--------- ----------
Total Stockholders' Equity 18,363 27,558
--------- ----------
Total Liabilities and Stockholders'
Equity $ 21,745 $ 32,282
========= ==========
IN8BIO, INC.
STATEMENTS OF OPERATIONS
(In thousands, except share and per share data)
Three Months Ended June Six Months Ended June
30, 30,
------------------------ ------------------------
2026 2025 2026 2025
----------- ---------- ----------- ----------
Operating
expenses:
Research and
development $ 2,493 $ 2,487 $ 5,106 $ 5,459
General and
administrative 2,442 2,714 5,095 5,402
---------- --------- ---------- ---------
Total operating
expenses 4,935 5,201 10,201 10,861
Interest income 154 107 330 217
---------- --------- ---------- ---------
Loss from
operations (4,781) (5,094) (9,871) (10,644)
---------- --------- ---------- ---------
Net loss $ (4,781) $ (5,094) $ (9,871) $ (10,644)
========== ========= ========== =========
Net loss per share
-- basic and
diluted $ (0.25) $ (1.24) $ (0.51) $ (3.65)
========== ========= ========== =========
Weighted-average
number of shares
used in computing
net loss per
common share,
basic and
diluted 19,467,091 4,119,153 19,468,087 2,920,157
========== ========= ========== =========
Comments